LAVAL, Canada, May 12, 2010 /PRNewswire/ -- Doug Peel, Executive Chairman of the Board of Directors of Algorithme Pharma, is pleased to announce the appointment of Christopher Perkin as the company's President and Chief Executive Officer. Mr. Perkin will officially join the company on May 31st.
This important appointment confirms Algorithme Pharma's commitment to the development of innovative strategies to better serve its clients and business partners. It also reflects the company's on- going efforts to become a world leader in clinical research and bioanalysis.
A native of England with a solid scientific background, Christopher Perkin is a seasoned executive and recognized leader with more than 30 years' experience in pharmaceutical development and business strategy. After holding several key positions at Huntingdon Research Center and Beecham Pharmaceuticals, Mr. Perkin joined the Charles River Laboratories in Senneville, Quebec, Canada, where he rose through the ranks to Corporate Senior Vice President - Global Preclinical Services with responsibility for operations in Asia and North America.
Mr. Perkin is a highly talented individual with world-class experience in our industry, and I am confident he wil create a dynamic environment with a renewed business focus that wil reinforce our industry-leading position and assure our status as a key international partner of pharmaceutical companies, said Doug Peel, Executive Chairman of the Board of Algorithme Pharma Holdings Inc.
About Algorithme Pharma
As a major global player in clinical research and bioanalysis, Algorithme Pharma provides a wide range of services for bioequivalence and early stage development (Phase I/IIa) studies to the pharmaceutical, and biotechnology industries. In addition to its multi-unit clinical facilities in Canada and the United Kingdom (more than 250 beds) and with its new dedicated Montreal state-of-the-art facility for Phase I clinical studies, Algorithme Pharma offers different services including protocol designs, CTD/ICH clinical reports, data management, biostatistics, quality assurance and regulatory affairs. Successfully audited by the US FDA, Canada TPD, Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES regulatory authorities, Algorithme Pharma conducts over 275 clinical trials per year. For further information: Mme Marie-Claude Boisvert, Vice President, Kilmer Capital Partners, +1-(514)-973-6077; http://www.algopharm.com
SOURCE: Algorithme Pharma
CONTACT: For further information: Mme Marie-Claude Boisvert, VicePresident, KilmerCapital Partners, +1-(514)-973-6077;http://www.algopharm.com
Comments